Exclusive | Suven Life Sciences puts demerged CRAMS arm on the block, engages Barclays as sale adviser According to its 2019 annual report, Suven Life Sciences posted total revenues of around Rs 688 crores and a net profit of around Rs 150 crores.
Suven Life Sciences has demerged its CRAMS business into one of its wholly owned subsidiaries Suven Pharmaceuticals Ltd. In consideration for the demerger, shareholders of Suven Pharma shall issue 1 share for each share of Suven Life Scie...
Suven Life Sciences has demerged its CRAMS business into one of its wholly owned subsidiaries Suven Pharmaceuticals Ltd. The CRAMS business is one of the largest revenue segments for Suven, contributing to ~97% on revenues in Q2FY20.
Suven Life share price plunges 19% after Alzheimer molecule disappoints in Phase 2 The triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.
Suven Life gains 2% after CRISIL assigns 'A' rating to co's long-term bank facilities CRISIL assigned 'A' rating to company's long-term bank facilities and placed on ‘Rating Watch with Positive Implications'.
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.